3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Vomiting
24
Nausea
20
Breast Neoplasms
8
Neoplasms
7
Multiple Myeloma
5
Lymphoma
5
Ovarian Neoplasms
4
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
4
Myeloproliferative Disorders
3
Carcinoma, Non-Small-Cell Lung
3
Testicular Neoplasms
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Neuroblastoma
2
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Interventions
tofacitinib
5
masitinib
1
desloratadine
1
apremilast
1
Etanercept
1
Aprepitant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pruritus
×
Aprepitant
×
Clear all
NCT02646020
2021-05-18
EGFR-TKIs
Sun Yat-sen University
Phase 2
Completed
138 enrolled